Carlsmed reports 58% revenue growth in Q1 2026, raises full-year guidance to $72-$77M

Carlsmed announced a 58% year-over-year revenue increase to $16.1 million in Q1 2026, driven by strong sales of its AI-enabled personalized spine surgery products. The company highlighted clinical data showing a 74% reduction in revision surgeries with its aprevo® implants, supporting its market differentiation. Carlsmed also launched new products including the corra™ cervical plating system and expanded its lumbar platform. It raised its full-year 2026 revenue guidance to $72-$77 million, expecting continued growth and innovation.